Literature DB >> 10459906

First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons.

R Coninx1, C Mathieu, M Debacker, F Mirzoev, A Ismaelov, R de Haller, D R Meddings.   

Abstract

BACKGROUND: We assessed a programme of tuberculosis control in a prison setting in Baku, Azerbaijan. The programme used first-line therapy and DOTS (directly observed treatment, short course).
METHODS: 467 patients had sputum-positive tuberculosis. Their treatment regimens followed WHO guidelines, and they had regular clinical examinations and dietary supplements. Isolates were tested by standard methods for resistance to isoniazid, rifampicin, ethambutol, and streptomycin in three laboratories. Treatment success was defined as three consecutive negative sputum smears at end of treatment. Factors independently associated with treatment failure were estimated by logistic regression.
FINDINGS: Drug-resistance data on admission were available for 131 patients. 55% of patients had strains of Mycobacterium tuberculosis resistant to two or more antibiotics. Mortality during treatment was 11%, and 13% of patients defaulted. Overall, treatment was successful in 54% of patients, and in 71% of those completing treatment. 104 patients completed a full treatment regimen and remained sputum-positive. Resistance to two or more antibiotics, a positive sputum result at the end of initial treatment, cavitary disease, and poor compliance were independently associated with treatment failure.
INTERPRETATION: The effectiveness of a DOTS programme with first-line therapy fell short of the 85% target set by WHO. First-line therapy may not be sufficient in settings with a high degree of resistance to antibiotics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459906     DOI: 10.1016/s0140-6736(98)08341-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

1.  Criteria for the control of drug-resistant tuberculosis.

Authors:  C Dye; B G Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Outbreak of isoniazid resistant tuberculosis in north London.

Authors:  M C Ruddy; A P Davies; M D Yates; S Yates; S Balasegaram; Y Drabu; B Patel; S Lozewicz; S Sen; M Bahl; E James; M Lipman; G Duckworth; J M Watson; M Piper; F A Drobniewski; H Maguire
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

3.  Evaluation of Etest for susceptibility testing of multidrug-resistant isolates of Mycobacterium tuberculosis.

Authors:  M H Hazbón; M del Socorro Orozco; L A Labrada; R Tovar; K A Weigle; A Wanger
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action.

Authors:  Maikel Boot; Susanna Commandeur; Amit K Subudhi; Meriem Bahira; Trever C Smith; Abdallah M Abdallah; Mae van Gemert; Joël Lelièvre; Lluís Ballell; Bree B Aldridge; Arnab Pain; Alexander Speer; Wilbert Bitter
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 5.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

6.  A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK.

Authors:  F Drobniewski; I Eltringham; C Graham; J G Magee; E G Smith; B Watt
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

7.  Pulmonary tuberculosis and drug resistance in Dhaka central jail, the largest prison in Bangladesh.

Authors:  Sayera Banu; Arman Hossain; Mohammad Khaja Mafij Uddin; Muhammad Reaj Uddin; Tahmeed Ahmed; Razia Khatun; Asif Mujtaba Mahmud; Khurshid Alam Hyder; Afzalunnessa Binte Lutfor; Md Sirajul Karim; Khalequ Zaman; Md Ashraful Islam Khan; Pravat Chandra Barua; Stephen P Luby
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

8.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

9.  Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Authors:  Francine Matthys; Leen Rigouts; Vinciane Sizaire; Natalia Vezhnina; Maryvonne Lecoq; Vera Golubeva; Françoise Portaels; Patrick Van der Stuyft; Michael Kimerling
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

10.  Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014.

Authors:  Sarah E Smith; Robert Pratt; Lisa Trieu; Pennan M Barry; Dzung T Thai; Shama Desai Ahuja; Sarita Shah
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.